Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia
- PMID: 15899583
- DOI: 10.1016/j.plefa.2005.03.002
Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia
Abstract
Adipose tissue of mice bearing a cachexia-inducing murine tumour (MAC16) shows increased expression of zinc-alpha(2)-glycoprotein (ZAG), a lipolytic factor thought to be responsible for the increased lipolysis. The anti-cachectic agent eicosapentaenoic acid (EPA) (0.5 g/kg) attenuated the loss of body weight in mice bearing the MAC16 tumour, and this was accompanied by downregulation of ZAG expression in both white and brown adipose tissue, as determined by Western blotting. Glucocorticoids may be responsible for the increased ZAG expression in adipose tissue. Dexamethasone (1.68 microM) stimulated lipolysis in 3T3-L1 adipocytes, and this effect was attenuated by EPA (50 microM). In addition the lipolytic action of dexamethasone was attenuated by anti-ZAG antibody, suggesting that the induction of lipolysis was mediated through an increase in ZAG expression. This was confirmed by Western blotting, which showed that dexamethasone (1.68 microM) induced a two-fold increase in ZAG expression in both cells and media, and that this was attenuated by EPA (50 microM). These results suggest that EPA may preserve adipose tissue in cachectic mice by downregulation of ZAG expression through interference with glucocorticoid signalling.
Similar articles
-
The role of glucocorticoids in the induction of zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia.Br J Cancer. 2005 Mar 14;92(5):876-81. doi: 10.1038/sj.bjc.6602404. Br J Cancer. 2005. PMID: 15714206 Free PMC article.
-
Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF).Br J Cancer. 2001 Sep 1;85(5):758-63. doi: 10.1054/bjoc.2001.1992. Br J Cancer. 2001. PMID: 11531264 Free PMC article.
-
Zinc-alpha2-glycoprotein in cachexia and obesity.Curr Opin Support Palliat Care. 2009 Dec;3(4):288-93. doi: 10.1097/SPC.0b013e328331c897. Curr Opin Support Palliat Care. 2009. PMID: 19823091 Review.
-
Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes.FEBS Lett. 2005 Jan 3;579(1):41-7. doi: 10.1016/j.febslet.2004.11.042. FEBS Lett. 2005. PMID: 15620688
-
Pathogenesis of cancer cachexia.J Support Oncol. 2003 Sep-Oct;1(3):159-68. J Support Oncol. 2003. PMID: 15334872 Review.
Cited by
-
Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.Support Care Cancer. 2006 Dec;14(12):1173-83. doi: 10.1007/s00520-006-0097-7. Epub 2006 Jul 4. Support Care Cancer. 2006. PMID: 16819628 Review.
-
Protective Effects of Omega-3 Fatty Acids in Cancer-Related Complications.Nutrients. 2019 Apr 26;11(5):945. doi: 10.3390/nu11050945. Nutrients. 2019. PMID: 31035457 Free PMC article. Review.
-
Thyroid hormone upregulates zinc-α2-glycoprotein production in the liver but not in adipose tissue.PLoS One. 2014 Jan 21;9(1):e85753. doi: 10.1371/journal.pone.0085753. eCollection 2014. PLoS One. 2014. PMID: 24465683 Free PMC article.
-
Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options.Front Oncol. 2020 Mar 4;10:298. doi: 10.3389/fonc.2020.00298. eCollection 2020. Front Oncol. 2020. PMID: 32195193 Free PMC article. Review.
-
Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise.J Cachexia Sarcopenia Muscle. 2011 Jun;2(2):95-104. doi: 10.1007/s13539-011-0028-4. Epub 2011 May 11. J Cachexia Sarcopenia Muscle. 2011. PMID: 21766055 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous